EGFR and non-small cell lung carcinoma: EGFR-activating mutations, 90% of which comprise 15 bp deletions in exon 19 or L858R point mutation in exon 21, occur in nearly 50% of Asian patients and 10–15% of Caucasian patients with NSCLC [1,2].